SWTX
vs
S&P 500

Over the past 12 months, SWTX has underperformed S&P 500, delivering a return of -1% compared to the S&P 500's 8% growth.
Stocks Performance
SWTX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
|
US |
E
|
Epizyme Inc
F:EPE
|
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
|
US |
S
|
Seagen Inc
F:SGT
|
|
NL |
![]() |
argenx SE
XBRU:ARGX
|
Performance Gap
SWTX vs S&P 500
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
|
US |
E
|
Epizyme Inc
F:EPE
|
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
|
US |
S
|
Seagen Inc
F:SGT
|
|
NL |
![]() |
argenx SE
XBRU:ARGX
|
Performance By Year
SWTX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
|
US |
E
|
Epizyme Inc
F:EPE
|
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
|
US |
S
|
Seagen Inc
F:SGT
|
|
NL |
![]() |
argenx SE
XBRU:ARGX
|
Competitors Performance
SpringWorks Therapeutics Inc vs Peers
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
UK |
E
|
Eight Capital Partners PLC
F:ECS
|
|
IN |
G
|
GTV Engineering Ltd
BSE:539479
|
|
MY |
C
|
Carimin Petroleum Bhd
KLSE:CARIMIN
|
|
US |
G
|
GE Vernova LLC
NYSE:GEV
|
|
NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
|
US |
![]() |
Schlumberger NV
NYSE:SLB
|
|
US |
B
|
Baker Hughes Co
NASDAQ:BKR
|
|
ID |
![]() |
Amman Mineral Internasional Tbk PT
IDX:AMMN
|
|
CH |
G
|
Galderma Group AG
SIX:GALD
|
|
US |
R
|
Reddit Inc
NYSE:RDDT
|
SpringWorks Therapeutics Inc
Glance View
SpringWorks Therapeutics Inc., a cutting-edge biopharmaceutical company, emerged from its inception as a strategic spin-out venture from the global pharmaceutical giant Pfizer. Born in 2017, the company cleverly positions itself at the forefront of the drug development process, with a keen focus on targeting rare diseases and cancer. SpringWorks leverages its robust pipeline of therapies, specifically designed to address significant unmet medical needs. Their approach revolves around the repurposing and reinvigoration of underappreciated and overlooked clinical molecules, which previously lacked the necessary backing to reach the market. This innovative approach allows SpringWorks to harness upstream R&D efforts while minimizing the typical time and resources required for de novo drug development. Earning its stripes in the field, SpringWorks generates revenue primarily through milestone and royalty agreements tied to its partnerships and co-development collaborations. Rather than relying solely on traditional sales of approved drugs, the company emphasizes strategic alliances with research institutions and pharmaceutical partners to advance its drug candidates. This co-development model extends its reach and augments the company's research capabilities, enabling SpringWorks to share risks and tap into broader resources. By nurturing innovations through collaboration, SpringWorks not only enriches its pipeline but also stands as a vanguard in transforming potential therapies into commercial realities, ultimately positioning itself as a linchpin in the orphan disease market.
